Takeda Rejects $480M AbbVie Claim In Del. Drug Shortage Suit
Takeda Pharmaceuticals urged a Delaware vice chancellor Thursday to reject AbbVie Endocrine Inc.'s call for a $480.7 million award to cover profits lost to Takeda's yearlong breach of a pact for...To view the full article, register now.
Already a subscriber? Click here to view full article